FindTrial
Sign In

A randomized controlled trial for improving effects of "KIMIE WHITE" or "CYSTATHIONE" on liver functions in alcohol drinkers

A randomized controlled trial for improving effects of "KIMIE WHITE" or "CYSTATHIONE" on liver functions in alcohol drinkers - A trial for improving effects of novel supplements on liver functions in drinkers

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000013168
Enrollment
30
Registered
2014-02-14
Start date
2014-01-15
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

Duration: 4 weeks Test material: KIMIE WHITE 6 (three times) tablets per day Duration: 4 weeks Test material: CYSTATHIONE 2 capsules per day (940mg/day) Duration: 4 weeks Test material: Place

Sponsors

ORTHOMEDICO Inc.
Lead Sponsor
Seishin-kai Medical Association Inc, Takara Medical Clinic
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: a) Persons who have drinking habit

Exclusion criteria

Exclusion criteria: a) Persons who have previous medical history of malignancy, heart failure, or myocardial infarction b) Patients being treated for at least one of following diseases; atrial fibrillation, cardiac arrhythmia, hepatic disorder, renal disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, and other chronic disease c) Persons who take medicines, herbal medicines, or dietary supplements d) Persons who are allergic to medicines, or foods related to the test material of this trial e) Persons who have previous medical history of Pollinosis f) Smokers g) Persons who take dietary supplement or enriched food h) Pregnant women, lactating women, or women who want to get pregnant during the trial period i) Persons who have been enrolled in the other clinical trials within last 3 months before the agreement for the participation to this trial j) Persons who are judged not suitable to participate in this trial by physician.

Design outcomes

Primary

MeasureTime frame
Markers of liver function + Aspartate aminotransferase (AST) + alanine aminotransferase (ALT) + gamma-glutamyl transpeptidase (gamma-GTP) + alkaline phosphatase (ALP) + lactate dehydrogenase (LDH) + leucine aminopeptidase (LAP) + total bilirubin + direct bilirubin + indirect bilirubin + cholinesterase + zinc sulphate turbidity test (ZTT) + total protein—

Secondary

MeasureTime frame
Subjective symptoms measured by Likert scales—

Countries

Japan

Contacts

Public ContactNaoko SUZUKI

ORTHOMEDICO, Inc. R&D Department

nao@orthomedico.jp03-3818-0610

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026